Crystals, 2020 The cocrystal formation of pharmaceuticals can improve the various physical properties of drugs, such as solubility, without the need for chemical modification of the drug substances.
Maho Urano +6 more
doaj +1 more source
Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model
Brazilian Journal of Cardiovascular Surgery, 2021 Introduction: To clarify the potential protective role of cilostazol on rat myocardial cells with ischemia-reperfusion injury (IRI) models. Methods: The study was conducted with three groups of 10 Wistar rats (control group, rats without any coronary ...
Mazlum Sahin +2 more
doaj +1 more source
PLoS ONE, 2022 PurposeDrug-eluting stents (DESs) play an important role in endovascular therapy (EVT) for femoropopliteal (FP) lesions. Cilostazol improves patency after bare-metal nitinol stent (BNS) implantation for femoropopliteal lesions.
Takashi Miura +10 more
doaj +1 more source
Cilostazol inhibits accumulation of triglyceride in aorta and platelet aggregation in cholesterol-fed rabbits. [PDF]
PLoS ONE, 2012 Cilostazol is clinically used for the treatment of ischemic symptoms in patients with chronic peripheral arterial obstruction and for the secondary prevention of brain infarction.
Hideki Ito +7 more
doaj +1 more source
More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]
, 2018 © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M +6 more
core +3 more sources
Silence of the limbs: pharmacological symptomatic treatment of intermittent claudication [PDF]
, 2010 Several oral "vasoactive" drugs claim to increase walking capacity in patients with intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline are the most studied molecules.
De Backer, Gui +4 more
core +1 more source
Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]
, 2018 © 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki +3 more
core +2 more sources
Effect of cilostazol on arteriovenous fistula in hemodialysis patients
Nefrología (English Edition), 2021 Background: The maturation and patency of permanent vascular access are critical in patients requiring hemodialysis. Although numerus trials have been attempted to achieve permanently patent vascular access, little have been noticeable.
Jae Wan Jeon +8 more
doaj +3 more sources
Conversion from cilostazol to OPC‐13015 linked to mitigation of cognitive impairment
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2021 Introduction Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than cilostazol.
Satoshi Saito +8 more
doaj +1 more source
Atomic-level characterization and cilostazol affinity of poly(lactic acid) nanoparticles conjugated with differentially charged hydrophilic molecules [PDF]
, 2018 Indexación: Scopus.M.F.M. acknowledges support from CONICYT-PFCHA/Doctorado Nacional/2014-21140225. M.M.M. thanks the FONCyT PICT-2015-2191, CONICET PIP 11220110100992, Secyt, Universidad Nacional de Cordoba. C.V.
Ludueña, M. +4 more
core +2 more sources